MCM
MSLE

MAI Capital Management’s Satellos Bioscience MSLE Stock Holding History

MAI Capital Management’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-140
Closed -$789 – 5101
2026
Q1 		$789 Buy
+140
New +$1.38K ﹤0.01% 4262

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

MAI Capital Management's MSLE Position: Q2 2026 in Review

MAI Capital Management sold out of Satellos Bioscience (MSLE) in Q2 2026, closing a stake of 140 shares — an estimated $789 sold.

MAI Capital Management first reported a position in MSLE in Q1 2026 and held it in 1 quarter. The position peaked at $789 in Q1 2026. 26 funds tracked by Wall St. Rank hold MSLE as of Q2 2026.

  • MAI Capital Management reported no remaining Satellos Bioscience position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 140 Satellos Bioscience shares in Q2 2026, an estimated $789.
  • MAI Capital Management first reported a position in Satellos Bioscience in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's Satellos Bioscience position peaked at $789 in Q1 2026.
  • 26 funds tracked by Wall St. Rank held Satellos Bioscience as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.